Near-infrared spectroscopy-derived lipid core burden index predicts adverse cardiovascular outcome in patients with coronary artery disease during long-term follow-up

European Heart Journal

Volumn 39, Issue 4, 2018, Pages 295-301

  Schuurman, Anne Sophie ^a,b   Vroegindewey, Maxime ^a,b   Kardys, Isabella ^a,b   Oemrawsingh, Rohit M ^a,b   Cheng, Jin M ^a,b   De Boer, Sanneke ^a,b   Garcia Garcia, Hector M ^c   Van Geuns, Robert Jan ^a,b   Regar, Evelyn S ^a,b,d   Daemen, Joost ^a,b   Van Mieghem, Nicolas M ^a,b   Serruys, Patrick W ^a,e   Boersma, Eric ^a,b   Akkerhuis, K Martijn ^a,b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^c WASHINGTON HOSPITAL CENTER   (United States)

^d UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^e IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Cardiovascular outcome; Lipid core burden index; Near infrared spectroscopy; Prognosis

Indexed keywords

ACUTE CORONARY SYNDROME; ADULT; ALL CAUSE MORTALITY; ARTICLE; CARDIOVASCULAR DISEASE ASSESSMENT; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; CORONARY ARTERY RECANALIZATION; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HAZARD RATIO; HIGH RISK PATIENT; HUMAN; INTRAVASCULAR ULTRASOUND; LIPID CORE BURDEN INDEX; MAJOR ADVERSE CARDIAC EVENT; MAJOR CLINICAL STUDY; MALE; NEAR INFRARED SPECTROSCOPY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; STABLE ANGINA PECTORIS; AGED; BLOOD; COMPLICATION; HEART MUSCLE REVASCULARIZATION; MIDDLE AGED; MORTALITY; PROCEDURES; SUDDEN CARDIAC DEATH;

LIPID;

ACUTE CORONARY SYNDROME; AGED; CORONARY ARTERY DISEASE; DEATH, SUDDEN, CARDIAC; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIPIDS; MALE; MIDDLE AGED; MYOCARDIAL REVASCULARIZATION; PROGNOSIS; RISK FACTORS; SPECTROSCOPY, NEAR-INFRARED;

EID: 85041189061     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehx247     Document Type: Article

References (19)

1. Virmani R, Kolodgie FD, Burke AP, Farb A, Schwartz SM. Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions. Arterioscler Thromb Vasc Biol 2000;20:1262-1275.
2. Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation 1995;92:657-671.
3. Glaser R, Selzer F, Faxon DP, Laskey WK, Cohen HA, Slater J, Detre KM, Wilensky RL. Clinical progression of incidental, asymptomatic lesions discovered during culprit vessel coronary intervention. Circulation 2005;111:143-149.
4. Jaross W, Neumeister V, Lattke P, Schuh D. Determination of cholesterol in atherosclerotic plaques using near infrared diffuse reflection spectroscopy. Atherosclerosis 1999;147:327-337.
5. Waxman S, Dixon SR, L'allier P, Moses JW, Petersen JL, Cutlip D, Tardif JC, Nesto RW, Muller JE, Hendricks MJ, Sum ST, Gardner CM, Goldstein JA, Stone GW, Krucoff MW. In vivo validation of a catheter-based near-infrared spectroscopy system for detection of lipid core coronary plaques: initial results of the SPECTACL study. JACC Cardiovasc Imaging 2009;2:858-868.
6. Goldstein JA, Madden SP, Sum ST, Dixon SR, Madder RD, Muller JE. Assessment of plaque composition with near-infrared spectroscopy. Curr Cardiovasc Imaging Rep 2011;4:298-308.
7. Moreno PR, Lodder RA, Purushothaman KR, Charash WE, O'connor WN, Muller JE. Detection of lipid pool, thin fibrous cap, and inflammatory cells in human aortic atherosclerotic plaques by near-infrared spectroscopy. Circulation 2002;105:923-927.
8. de Boer SP, Cheng JM, Garcia-Garcia HM, Oemrawsingh RM, van Geuns RJ, Regar E, Zijlstra F, Laaksonen R, Halperin E, Kleber ME, Koenig W, Boersma E, Serruys PW. Relation of genetic profile and novel circulating biomarkers with coronary plaque phenotype as determined by intravascular ultrasound: rationale and design of the ATHEROREMO-IVUS study. Euro Intervention 2014;10:953-960.
9. Simsek C, Garcia-Garcia HM, van Geuns RJ, Magro M, Girasis C, van Mieghem N, Lenzen M, de Boer S, Regar E, van der Giessen W, Raichlen J, Duckers HJ, Zijlstra F, van der Steen T, Boersma E, Serruys PW. The ability of high dose rosuvastatin to improve plaque composition in non-intervened coronary arteries: rationale and design of the Integrated Biomarker and Imaging Study-3 (IBIS-3). Euro Intervention 2012;8:235-241.
10. Oemrawsingh RM, Cheng JM, Garcia-Garcia HM, van Geuns RJ, de Boer SP, Simsek C, Kardys I, Lenzen MJ, van Domburg RT, Regar E, Serruys PW, Akkerhuis KM, Boersma E. Near-infrared spectroscopy predicts cardiovascular outcome in patients with coronary artery disease. J Am Coll Cardiol 2014;64:2510-2518.
11. The Task Force on the management of stable coronary artery disease of the European Society of Cardiology. 2013 ESC guidelines on the management of stable coronary artery disease. Eur Heart J 2013;34:2949-3003.
12. The Task Force on myocardial revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). 2014 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J 2014;35:2541-2619.
13. Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC). ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2012;33:2569-2619.
14. Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 2016;37:267-315.
15. Weisz G. Two-year results of the COLOR trial presented at TCT 2016: study indicates PCI of NIRS-defined lipid-rich plaque is safe and not associated with a greater incidence of adverse outcomes compared to PCI of non lipid-rich plaque. Cardiovascular Research Foundation 2016. https://www.eurekalert.org/pub-releases/2016-11/crf-tro110116.php (28 April 2017).
16. Nicholls SJ, Hsu A, Wolski K, Hu B, Bayturan O, Lavoie A, Uno K, Tuzcu EM, Nissen SE. Intravascular ultrasound-derived measures of coronary atherosclerotic plaque burden and clinical outcome. J Am Coll Cardiol 2010;55:2399-2407.
17. Kini AS, Baber U, Kovacic JC, Limaye A, Ali ZA, Sweeny J, Maehara A, Mehran R, Dangas G, Mintz GS, Fuster V, Narula J, Sharma SK, Moreno PR. Changes in plaque lipid content after short-term intensive versus standard statin therapy: the YELLOW trial (reduction in yellow plaque by aggressive lipid-lowering therapy). J Am Coll Cardiol 2013;62:21-29.
18. Oemrawsingh RM, Garcia-Garcia HM, van Geuns RJ, Lenzen MJ, Simsek C, de Boer SP, Van Mieghem NM, Regar E, de Jaegere PP, Akkerhuis KM, Ligthart JM, Zijlstra F, Serruys PW, Boersma E. Integrated Biomarker and Imaging Study 3 (IBIS-3) to assess the ability of rosuvastatin to decrease necrotic core in coronary arteries. Euro Intervention 2016;12:734-739.
19. Nicholls SJ, Puri R, Anderson T, Ballantyne CM, Cho L, Kastelein JJ, Koenig W, Somaratne R, Kassahun H, Yang J, Wasserman SM, Scott R, Ungi I, Podolec J, Ophuis AO, Cornel JH, Borgman M, Brennan DM, Nissen SE. Effect of evolocumab on progression of coronary disease in statin-treated patients: the GLAGOV randomized clinical trial. Jama 2016;316:2373-2384.